1
|
Liulu X, Balaji P, Barber J, De Silva K, Murray T, Hickey A, Campbell T, Harris J, Gee H, Ahern V, Kumar S, Hau E, Qian PC. Radiation therapy for ventricular arrhythmias. J Med Imaging Radiat Oncol 2024. [PMID: 38698577 DOI: 10.1111/1754-9485.13662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Accepted: 04/15/2024] [Indexed: 05/05/2024]
Abstract
Ventricular arrhythmias (VA) can be life-threatening arrhythmias that result in significant morbidity and mortality. Catheter ablation (CA) is an invasive treatment modality that can be effective in the treatment of VA where medications fail. Recurrence occurs commonly following CA due to an inability to deliver lesions of adequate depth to cauterise the electrical circuits that drive VA or reach areas of scar responsible for VA. Stereotactic body radiotherapy is a non-invasive treatment modality that allows volumetric delivery of energy to treat circuits that cannot be reached by CA. It overcomes the weaknesses of CA and has been successfully utilised in small clinical trials to treat refractory VA. This article summarises the current evidence for this novel treatment modality and the steps that will be required to bring it to the forefront of VA treatment.
Collapse
Affiliation(s)
- Xingzhou Liulu
- Cardiology Department, Royal North Shore Hospital, Sydney, New South Wales, Australia
| | - Poornima Balaji
- Cardiology Department, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia
- Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
| | - Jeffrey Barber
- Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Kasun De Silva
- Cardiology Department, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia
- Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
| | - Tiarne Murray
- Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
| | - Andrew Hickey
- Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
| | - Timothy Campbell
- Cardiology Department, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia
- Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
| | - Jill Harris
- Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
| | - Harriet Gee
- Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Verity Ahern
- Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Saurabh Kumar
- Cardiology Department, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia
- Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Eric Hau
- Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Translational Radiation Biology and Oncology Laboratory, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
- Blacktown Hematology and Cancer Centre, Blacktown Hospital, Blacktown, New South Wales, Australia
| | - Pierre C Qian
- Cardiology Department, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia
- Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
2
|
Kawamura M, Shimojo M, Inden Y, Kamomae T, Okudaira K, Komada T, Aoki S, Shindo Y, Yasui R, Yanagi Y, Okumura M, Yamada T, Kozai Y, Oie Y, Kato Y, Ishihara S, Murohara T, Naganawa S. Stereotactic radiotherapy for ventricular tachycardia: A study protocol. F1000Res 2023; 12:798. [PMID: 38204487 PMCID: PMC10776963 DOI: 10.12688/f1000research.138758.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/07/2023] [Indexed: 01/12/2024] Open
Abstract
Background Currently, the standard curative treatment for ventricular tachycardia (VT) and ventricular fibrillation (VF) is radiofrequency catheter ablation. However, when the VT circuit is deep in the myocardium, the catheter may not be delivered, and a new, minimally invasive treatment using different energies is desired. Methods This is a protocol paper for a feasibility study designed to provide stereotactic radiotherapy for refractory VT not cured by catheter ablation after at least one catheter ablation. The primary end point is to evaluate the short-term safety of this treatment and the secondary endpoint is to evaluate its efficacy as assessed by the reduction in VT episode. Cyberknife M6 radiosurgery system will be used for treatment, and the prescribed dose to the target will be 25Gy in one fraction. The study will be conducted on three patients. Conclusion Since catheter ablation is the only treatment option for VT that is covered by insurance in Japan, there is currently no other treatment for VT/VF that cannot be cured by catheter ablation. We hope that this feasibility study will provide hope for patients who are currently under the stress of ICD activation. Trial registration The study has been registered in the Japan Registry of Clinical Trials (jRCTs042230030).
Collapse
Affiliation(s)
- Mariko Kawamura
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Masafumi Shimojo
- Cardiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Yasuya Inden
- Cardiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Takeshi Kamomae
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Kuniyasu Okudaira
- Radiological Technology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Tomohiro Komada
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Sumire Aoki
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Yurika Shindo
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Ryotaro Yasui
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Yusuke Yanagi
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Masayuki Okumura
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Takehiro Yamada
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Yuka Kozai
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Yumi Oie
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Yutaka Kato
- Radiological Technology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Shunichi Ishihara
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Toyoaki Murohara
- Cardiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| | - Shinji Naganawa
- Radiology, Nagoya University Hospital, Nagoya, Aichi Prefecture, Japan
| |
Collapse
|
3
|
Di Monaco A, Gregucci F, Bonaparte I, Romanazzi I, Troisi F, Surgo A, Vitulano N, Quadrini F, Valenti N, Carbonara R, Di Guglielmo FC, Ludovico E, Calbi R, Guida P, Ciliberti MP, Fiorentino A, Grimaldi M. Linear accelerator-based stereotactic arrhythmia radioablation for paroxysmal atrial fibrillation in elderly: a prospective phase II trial. Europace 2023; 25:euad344. [PMID: 37988294 PMCID: PMC10700012 DOI: 10.1093/europace/euad344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2023] [Revised: 10/13/2023] [Accepted: 11/17/2023] [Indexed: 11/23/2023] Open
Abstract
AIMS Stereotactic arrhythmia radioablation (STAR) is a novel therapeutic approach for cardiac arrhythmias. The aim of this trial is to investigate the feasibility of STAR for the treatment of paroxysmal atrial fibrillation (AF) in elderly patients. METHODS AND RESULTS Inclusion criteria were age >70 years, symptomatic AF, antiarrhythmic drugs failure, or intolerance. All patients underwent to 4D cardiac computed tomography simulation. The clinical target volume was identified in the area around pulmonary veins (PV). Stereotactic arrhythmia radioablation was performed with a total dose of 25 Gy (single fraction) delivered in 3 min. Twenty patients were enrolled and 18 underwent STAR. One patient withdrew informed consent before treatment and one patient was excluded due to unfavourable oesophagus position. With a median follow-up (FU) of 16 months (range 12-23), no acute toxicity more than Grade 3 was reported. Five patients had a Grade 1 oesophagitis 24 h after STAR; eight patients had an asymptomatic Grade 1 pericardial effusion, and one patient had a torsade de pointes treated effectively by electrical cardioversion and subsequent cardiac implantable cardioverter-defibrillator implantation. Most patients had a significant reduction in AF episodes. Five patients, due to arrhythmias recurrences after STAR, performed electrophysiological study documenting successful PV isolation. Finally, a significant improvement of quality of life was documented (48 ± 15 at enrolment vs. 75 ± 15 at 12 months FU; P < 0.001). CONCLUSION The present phase II trial demonstrated the feasibility of STAR in paroxysmal AF elderly patients and its potential role in increasing the quality of life. Surely, more robust data are needed about safety and efficacy. TRIAL REGISTRATION ClinicalTrials.gov: NCT04575662.
Collapse
Affiliation(s)
- Antonio Di Monaco
- Department of Cardiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti 70021, Bari, Italy
- Department of Clinical and Experimental Medicine, University of Foggia, Viale Luigi Pinto 71122 Foggia, Italy
| | - Fabiana Gregucci
- Department of Radiation Oncology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti, Bari, Italy
| | - Ilaria Bonaparte
- Department of Radiation Oncology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti, Bari, Italy
| | - Imma Romanazzi
- Department of Cardiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti 70021, Bari, Italy
| | - Federica Troisi
- Department of Cardiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti 70021, Bari, Italy
| | - Alessia Surgo
- Department of Radiation Oncology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti, Bari, Italy
| | - Nicola Vitulano
- Department of Cardiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti 70021, Bari, Italy
| | - Federico Quadrini
- Department of Cardiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti 70021, Bari, Italy
| | - Noemi Valenti
- Department of Cardiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti 70021, Bari, Italy
| | - Roberta Carbonara
- Department of Radiation Oncology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti, Bari, Italy
| | | | - Elena Ludovico
- Department of Radiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti, Bari, Italy
| | - Roberto Calbi
- Department of Radiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti, Bari, Italy
| | - Pietro Guida
- Department of Cardiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti 70021, Bari, Italy
| | - Maria Paola Ciliberti
- Department of Radiation Oncology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti, Bari, Italy
| | - Alba Fiorentino
- Department of Radiation Oncology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti, Bari, Italy
- Department of Medicine and Surgery, LUM University, Casamassima, Bari, Italy
| | - Massimo Grimaldi
- Department of Cardiology, General Regional Hospital ‘F. Miulli’, Acquaviva delle Fonti 70021, Bari, Italy
| |
Collapse
|
4
|
Bonaparte I, Gregucci F, Di Monaco A, Troisi F, Surgo A, Ludovico E, Carbonara R, Paulicelli E, Sanfrancesco G, De Pascali C, Vitulano N, Quadrini F, Ciliberti MP, Romanazzi I, Di Guglielmo FC, Cusumano D, Calbi R, Grimaldi M, Fiorentino A. Phase II Trial of LINAC-Based STereotactic Arrhythmia Radioablation (STAR) for Paroxysmal Atrial Fibrillation in Elderly: Planning and Dosimetric Point of View. J Pers Med 2023; 13:jpm13040596. [PMID: 37108982 PMCID: PMC10143465 DOI: 10.3390/jpm13040596] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 03/13/2023] [Accepted: 03/26/2023] [Indexed: 03/31/2023] Open
Abstract
Purpose: Approaching treatment for elderly patients with atrial fibrillation is difficult. A prospective phase II trial evaluating LINAC-based stereotactic arrhythmia radioablation (STAR) safety in this population started in 2021. Dosimetric and planning data were reported. Materials and Methods: A vac-lock bag was used for immobilization in the supine position and a computed tomography (CT, 1 mm) was performed. The clinical target volume (CTV) was defined as the area around the pulmonary veins. An internal target volume (ITV) was added to the CTV to compensate heart and respiratory movement. The planning target volume (PTV) was defined by adding 0–3 mm to the ITV. STAR was performed during free-breathing with a PTV prescription total dose (Dp) of 25 Gy/1 fraction. Flattening filter-free volumetric-modulated arc therapy plans were generated, optimized, and delivered by TrueBeamTM. Image-guided radiotherapy with cone-beam CT and surface-guided radiotherapy with Align-RT (Vision RT) were employed. Results: From May 2021 to March 2022, 10 elderly patients were treated. Mean CTVs, ITVs, and PTVs were 23.6 cc, 44.32 cc, and 62.9 cc, respectively; the mean prescription isodose level and D2% were 76.5% and 31.2 Gy, respectively. The average heart and left anterior descending artery (LAD) Dmean were 3.9 and 6.3 Gy, respectively; the mean Dmax for LAD, spinal cord, left and right bronchus, and esophagus were 11.2, 7.5, 14.3, 12.4, and 13.6 Gy, respectively. The overall treatment time (OTT) was 3 min. Conclusions: The data showed an optimal target coverage, sparing surrounding tissue, in 3 min of OTT. LINAC-based STAR for AF could represent a valid non-invasive alternative for elderly patients who were excluded from catheter ablation.
Collapse
|
5
|
Non-Oncological Radiotherapy: A Review of Modern Approaches. J Pers Med 2022; 12:jpm12101677. [PMID: 36294816 PMCID: PMC9605240 DOI: 10.3390/jpm12101677] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 10/04/2022] [Accepted: 10/06/2022] [Indexed: 11/05/2022] Open
Abstract
Despite being usually delivered in oncological patients, radiotherapy can be used as a successful treatment for several non-malignant disorders. Even though this use of radiotherapy has been scarcely investigated since the 1950s, more recent interest has actually shed the light on this approach. Thus, the aim of this narrative review is to analyze the applications of non-oncological radiotherapy in different disorders. Key references were derived from a PubMed query. Hand searching and clinicaltrials.gov were also used. This review contains a narrative report and a critical discussion of non-oncological radiotherapy approaches. In conclusion, non-oncological radiotherapy is a safe and efficacious approach to treat several disorders that needs to be further investigated and used in clinical practice.
Collapse
|
6
|
Kluge A, Ehrbar S, Grehn M, Fleckenstein J, Baus WW, Siebert FA, Schweikard A, Andratschke N, Mayinger MC, Boda-Heggemann J, Buergy D, Celik E, Krug D, Kovacs B, Saguner AM, Rudic B, Bergengruen P, Boldt LH, Stauber A, Zaman A, Bonnemeier H, Dunst J, Budach V, Blanck O, Mehrhof F. Treatment Planning for Cardiac Radioablation: Multicenter Multiplatform Benchmarking for the XXX Trial. Int J Radiat Oncol Biol Phys 2022; 114:360-372. [PMID: 35716847 DOI: 10.1016/j.ijrobp.2022.06.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Revised: 05/15/2022] [Accepted: 06/05/2022] [Indexed: 10/18/2022]
Abstract
PURPOSE Cardiac radioablation is a novel treatment option for patients with refractory ventricular tachycardia (VT) unsuitable for catheter ablation. The quality of treatment planning depends on dose specifications, platform capabilities, and experience of the treating staff. To harmonize the treatment planning, benchmarking of this process is necessary for multicenter clinical studies such as the XXX trial. METHODS AND MATERIALS Planning computed tomography data and consensus structures from three patients were sent to five academic centers for independent plan development using a variety of platforms and techniques with the XXX study protocol serving as guideline. Three-dimensional dose distributions and treatment plan details were collected and analyzed. In addition, an objective relative plan quality ranking system for VT treatments was established. RESULTS For each case, three coplanar volumetric modulated arc (VMAT) plans for C-arm linear accelerators (LINAC) and three non-coplanar treatment plans for robotic arm LINAC were generated. All plans were suitable for clinical applications with minor deviations from study guidelines in most centers. Eleven of 18 treatment plans showed maximal one minor deviation each for target and cardiac substructures. However, dose-volume histograms showed substantial differences: in one case, the PTV≥30Gy ranged from 0.0% to 79.9% and the RIVA V14Gy ranged from 4.0% to 45.4%. Overall, the VMAT plans had steeper dose gradients in the high dose region, while the plans for the robotic arm LINAC had smaller low dose regions. Thereby, VMAT plans required only about half as many monitor units, resulting in shorter delivery times, possibly an important factor in treatment outcome. CONCLUSIONS Cardiac radioablation is feasible with robotic arm and C-arm LINAC systems with comparable plan quality. Although cross-center training and best practice guidelines have been provided, further recommendations, especially for cardiac substructures, and ranking of dose guidelines will be helpful to optimize cardiac radioablation outcomes.
Collapse
Affiliation(s)
- Anne Kluge
- Klinik für Radioonkologie und Strahlentherapie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Stefanie Ehrbar
- Klinik für Radio-Onkologie, UniversitätsSpital Zürich, University of Zurich, Zürich, CH
| | - Melanie Grehn
- Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany
| | - Jens Fleckenstein
- Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Wolfgang W Baus
- Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Frank-Andre Siebert
- Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany
| | - Achim Schweikard
- University of Lübeck, Institute for Robotic and Cognitive Systems, Lübeck, Germany
| | - Nicolaus Andratschke
- Klinik für Radio-Onkologie, UniversitätsSpital Zürich, University of Zurich, Zürich, CH
| | - Michael C Mayinger
- Klinik für Radio-Onkologie, UniversitätsSpital Zürich, University of Zurich, Zürich, CH
| | - Judit Boda-Heggemann
- Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Daniel Buergy
- Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Eren Celik
- Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - David Krug
- Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany
| | - Boldizsar Kovacs
- Universitäres Herzzentrum, Klinik für Kardiologie, UniversitätsSpital Zürich, University of Zurich, Zürich, CH
| | - Ardan M Saguner
- Universitäres Herzzentrum, Klinik für Kardiologie, UniversitätsSpital Zürich, University of Zurich, Zürich, CH
| | - Boris Rudic
- Medizinische Klinik, Universitätsmedizin Mannheim and German Center for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Mannheim, Germany
| | - Paula Bergengruen
- Klinik für Radioonkologie und Strahlentherapie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Leif-Hendrik Boldt
- Med. Klinik m.S. Kardiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Annina Stauber
- Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Adrian Zaman
- Klinik für Innere Medizin III, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Hendrik Bonnemeier
- Klinik für Innere Medizin III, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Jürgen Dunst
- Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany
| | - Volker Budach
- Klinik für Radioonkologie und Strahlentherapie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Oliver Blanck
- Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany
| | - Felix Mehrhof
- Klinik für Radioonkologie und Strahlentherapie, Charité - Universitätsmedizin Berlin, Berlin, Germany.
| |
Collapse
|
7
|
Di Monaco A, Gregucci F, Bonaparte I, Troisi F, Surgo A, Di Molfetta D, Vitulano N, Quadrini F, Carbonara R, Ludovico E, Ciliberti MP, Fiorentino A, Grimaldi M. First Pulmonary Vein Isolation Using LINAC-Based STAR. Circ Arrhythm Electrophysiol 2022; 15:e010880. [PMID: 35649117 DOI: 10.1161/circep.122.010880] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Antonio Di Monaco
- Department of Cardiology (A.D.M., F.T., N.V., F.Q., M.G.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari.,Department of Clinical and Experimental Medicine, University of Foggia, Italy (A.D.M.)
| | - Fabiana Gregucci
- Department of Radiation Oncology (F.G., I.B., A.S., R.C., M.P.C., A.F.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Ilaria Bonaparte
- Department of Radiation Oncology (F.G., I.B., A.S., R.C., M.P.C., A.F.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Federica Troisi
- Department of Cardiology (A.D.M., F.T., N.V., F.Q., M.G.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Alessia Surgo
- Department of Radiation Oncology (F.G., I.B., A.S., R.C., M.P.C., A.F.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Domenico Di Molfetta
- Department of Radialogy (D.D.M., E.L.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Nicola Vitulano
- Department of Cardiology (A.D.M., F.T., N.V., F.Q., M.G.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Federico Quadrini
- Department of Cardiology (A.D.M., F.T., N.V., F.Q., M.G.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Roberta Carbonara
- Department of Radiation Oncology (F.G., I.B., A.S., R.C., M.P.C., A.F.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Elena Ludovico
- Department of Radialogy (D.D.M., E.L.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Maria Paola Ciliberti
- Department of Radiation Oncology (F.G., I.B., A.S., R.C., M.P.C., A.F.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Alba Fiorentino
- Department of Radiation Oncology (F.G., I.B., A.S., R.C., M.P.C., A.F.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| | - Massimo Grimaldi
- Department of Cardiology (A.D.M., F.T., N.V., F.Q., M.G.), General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari
| |
Collapse
|
8
|
Kurzelowski R, Latusek T, Miszczyk M, Jadczyk T, Bednarek J, Sajdok M, Gołba KS, Wojakowski W, Wita K, Gardas R, Dolla Ł, Bekman A, Grza̧dziel A, Blamek S. Radiosurgery in Treatment of Ventricular Tachycardia – Initial Experience Within the Polish SMART-VT Trial. Front Cardiovasc Med 2022; 9:874661. [PMID: 35509272 PMCID: PMC9058092 DOI: 10.3389/fcvm.2022.874661] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2022] [Accepted: 03/28/2022] [Indexed: 11/13/2022] Open
Abstract
BackgroundStereotactic Arrhythmia Radioablation (STAR) is an emerging treatment modality for patients with sustained ventricular tachycardia (VT) and refractory to treatment with drugs and radiofrequency catheter ablation (RFA). It is believed that up to 12–17% of patients experience recurrence of VT within 1 year of follow-up; thus, novel therapeutic options are needed. The aim of this article is to present initial experience within a novel treatment modality for VT.Case SummaryTwo patients with a medical history of coronary artery disease and heart failure with reduced left ventricle (LV) ejection fraction, after implantation of cardioverter-defibrillator (ICD) and previous unsuccessful RFAs owing to sustained VT were admitted to the cardiology department due to recurrence of sustained VT episodes. With electroanatomical mapping (EAM), the VT substrate in LV has been confirmed and specified. In order to determine the target volume for radioablation, contrast-enhanced computed tomography was performed and the arrhythmia substrate was contoured using EAM data. Using the Volumetric Modulated Arc Therapy technique and three 6 MeV flattening filter-free photon beam fields, a single dose of 25 Gy was delivered to the target volume structure located in the apex and anterior apical segments of LV in the first patient and in the apex, anterolateral and inferior apical segments of the second patient. In both cases, volumes of the target structures were comparable. Interrogation of the implanted ICD at follow-up visits throughout 6 months after the treatment revealed no VT episodes in the first patient and sudden periprocedural increase in VT burden with a subsequent gradual decrease of ventricular arrhythmia to only two non-sustained episodes at the end of the follow-up period in case of the second patient. A significant reduction in premature ventricular contractions burden was observed compared to the pre-treatment period. No noticeable deterioration in LV function was noted, nor any adverse effects of radiosurgery associated with the implanted device.ConclusionThe early response to STAR can be unpredictable and probably does not reflect the final outcome of irradiation. Close monitoring of patients, especially in the early period after irradiation is crucial to properly handle potentially harmful early reactions to STAR.
Collapse
Affiliation(s)
- Radosław Kurzelowski
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
- *Correspondence: Radosław Kurzelowski,
| | - Tomasz Latusek
- Department of Radiotherapy, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Marcin Miszczyk
- Department of Radiotherapy, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Tomasz Jadczyk
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
- Interventional Cardiac Electrophysiology Group, International Clinical Research Center, St. Anne’s University Hospital Brno, Brno, Czechia
| | - Jacek Bednarek
- Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland
- Department of Electrocardiology, Prof. Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland
- Department of Electrocardiology, John Paul II Hospital, Kraków, Poland
| | - Mateusz Sajdok
- Department of Electrocardiology, Prof. Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland
| | - Krzysztof S. Gołba
- Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland
- Department of Electrocardiology, Prof. Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland
| | - Wojciech Wojakowski
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Krystian Wita
- First Department of Cardiology, Medical University of Silesia, Katowice, Poland
| | - Rafał Gardas
- Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland
- Department of Electrocardiology, Prof. Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland
| | - Łukasz Dolla
- Department of Radiotherapy Planning, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Adam Bekman
- Department of Medical Physics, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Aleksandra Grza̧dziel
- Department of Radiotherapy Planning, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Sławomir Blamek
- Department of Radiotherapy, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| |
Collapse
|
9
|
Di Monaco A, Gregucci F, Bonaparte I, Troisi F, Surgo A, Di Molfetta D, Vitulano N, Quadrini F, Carbonara R, Martinelli G, Guida P, Ciliberti MP, Fiorentino A, Grimaldi M. Paroxysmal Atrial Fibrillation in Elderly: Worldwide Preliminary Data of LINAC-Based Stereotactic Arrhythmia Radioablation Prospective Phase II Trial. Front Cardiovasc Med 2022; 9:832446. [PMID: 35310997 PMCID: PMC8924125 DOI: 10.3389/fcvm.2022.832446] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Accepted: 02/08/2022] [Indexed: 12/31/2022] Open
Abstract
Treatment approach for elderly patients with atrial fibrillation (AF) is difficult. The present prospective phase-II trial evaluated LINAC-based stereotactic arrhythmia radioablation safety in this population. The reported data of the first 5 patients worldwide, showed no side effects, absence of AF episodes and without antiarrhythmic drugs.Trial Registration:ClinicalTrials.gov, identifier: NCT04575662.
Collapse
Affiliation(s)
- Antonio Di Monaco
- Department of Cardiology, General Regional Hospital F. Miulli, Bari, Italy
- Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
| | - Fabiana Gregucci
- Department of Radiation Oncology, General Regional Hospital F. Miulli, Bari, Italy
| | - Ilaria Bonaparte
- Department of Radiation Oncology, General Regional Hospital F. Miulli, Bari, Italy
| | - Federica Troisi
- Department of Cardiology, General Regional Hospital F. Miulli, Bari, Italy
| | - Alessia Surgo
- Department of Radiation Oncology, General Regional Hospital F. Miulli, Bari, Italy
| | | | - Nicola Vitulano
- Department of Cardiology, General Regional Hospital F. Miulli, Bari, Italy
| | - Federico Quadrini
- Department of Cardiology, General Regional Hospital F. Miulli, Bari, Italy
| | - Roberta Carbonara
- Department of Radiation Oncology, General Regional Hospital F. Miulli, Bari, Italy
| | - Gaetano Martinelli
- Department of Radiology, General Regional Hospital F. Miulli, Bari, Italy
| | - Pietro Guida
- Department of Cardiology, General Regional Hospital F. Miulli, Bari, Italy
| | | | - Alba Fiorentino
- Department of Radiation Oncology, General Regional Hospital F. Miulli, Bari, Italy
- *Correspondence: Alba Fiorentino
| | - Massimo Grimaldi
- Department of Cardiology, General Regional Hospital F. Miulli, Bari, Italy
| |
Collapse
|